Skip to main content
Figure 8 | BMC Medical Research Methodology

Figure 8

From: Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)

Figure 8

All-cause mortality relative risk reduction and BP difference. Upper graphs: Left: Scatterplot of all-cause mortality (ACM) relative risk reduction (RRR) and systolic blood pressure difference reduction showing the trials labelled by trial name. Middle: scatterplot weighted by trial size and by trial weighted least squares regression of all-cause mortality relative risk reduction and systolic blood pressure difference reduction assuming no measurement error (reliability coefficient = 1.0). Right: scatterplot weighted by trial size and by trial weighted least squares regression of all-cause mortality relative risk reduction and systolic blood pressure difference reduction assuming measurement error (reliability coefficient = 0.7). Lower graphs: show the results for diastolic blood pressure. The upper and lower bold solid lines are the upper and lower 95% prediction limits, the dashed inner lines are the 95% confidence limits, the dot-dash centre line is the mean regression line. There is no Surrogate Threshold Effect (STE) to impute an all-cause mortality benefit in a new trial.

Back to article page